H3 Biomedicine

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Although targeted therapies are initially effective, resistance inevitably emerges. Several methods, such as genetic analysis of resistant clinical specimens, have… Read More

H3 Biomedicine to Present Data on SF3B1 Program at 2015 American Society of Hematology Meeting

Updated data on company’s lead hematological program to be highlighted in poster presentation Read More

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point

Recurrent mutations in the spliceosome are observed in several human cancers, but their functional and therapeutic significance remains elusive. SF3B1,… Read More

H3 Biomedicine Publishes Preclinical Data Describing Mechanistic Insights into Splicing Factor Mutations in Multiple Cancers

Article published in current issue of Cell Reports details that SF3B1 mutations found in cancer use alternate branch point and… Read More

H3 Biomedicine’s Dr. Lihua Yu Honored in PharmaVOICE 100

In her position as VP, data science and information technology, at H3 Biomedicine, Lihua Yu, Ph.D., is driving the expanded… Read More

SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition

Mutations affecting spliceosomal proteins are the most common mutations in patients with myelodysplastic syndromes (MDS), but their role in MDS… Read More

H3 Biomedicine to Present Early-Stage Cancer Research at the 2015 American Association of Cancer Research Annual Meeting

Data to highlight impact of H3’s splicing modulation platform Read More